Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2010
Jurisdiction: Incorporated in Alberta, Canada; listed on NASDAQ Capital Market (ONCY) and TSX (ONC).
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on REOLYSIN®, an oncolytic virus therapeutic designed to target cancer cells with an activated Ras pathway. The company has no commercial product sales and relies on equity financing to fund research and development (R&D) and clinical trials.
Key Financial Metrics (2010)
| Metric | 2010 (Cdn$) | 2009 (Cdn$) |
|---|---|---|
| Revenue | — | — |
| Net Loss (Canadian GAAP) | (19,973,772) | (16,231,249) |
| Net Loss (U.S. GAAP) | (24,815,721) | (14,999,569) |
| Loss Per Share (Basic/Diluted, Cdn GAAP) | (0.32) | (0.33) |
| Research & Development Expenses | 12,191,809 | 11,606,514 |
| Stock-Based Compensation | 3,251,041 | 424,273 |
| Cash and Cash Equivalents (End of Period) | 39,296,682 | 32,448,939 |
| Short-Term Investments | 3,609,246 | 1,679,937 |
| Total Assets | 44,432,442 | 35,593,391 |
| Shareholders' Equity (Cdn GAAP) | 41,931,760 | 31,366,458 |
| Accumulated Deficit | (138,761,772) | (118,788,000) |
Note: All figures are in Canadian Dollars unless otherwise specified. The company reported no debt other than trade accounts payable.
Material Changes vs. Prior Period
- Increased Net Loss: The net loss under Canadian GAAP increased by approximately 23% to $20.0 million from $16.2 million in 2009. Under U.S. GAAP, the loss increased significantly to $24.8 million, primarily due to a $4.8 million charge related to the revaluation of warrant liabilities.
- Financing Activity: In November 2010, the company completed a bought deal financing, issuing 6,256,000 units for net cash proceeds of approximately $27.3 million. This significantly bolstered liquidity compared to 2009.
- Stock-Based Compensation: Stock-based compensation expense surged to $3.25 million in 2010 from $0.42 million in 2009, reflecting increased option grants to employees and directors.
- Investment in BCBC: The company increased its stake in British Canadian Biosciences Corp. (BCBC) to 70% in late 2010. Following BCBC's suspension of operations, this investment was reclassified as an "Asset Held for Sale" valued at $735,681.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Progress: The company is actively enrolling patients in a Phase III clinical trial (REO 018) for squamous cell carcinoma of the head and neck. Several Phase I and II trials are ongoing for various indications including colorectal, lung, and pancreatic cancers.
- Expenditure Trends: Management expects expenditures to increase in 2011 due to the Phase III trial enrollment, support for other clinical trials, and costs associated with manufacturing validation and commercial scale-up.
- Capital Requirements: The company anticipates needing additional financing in the future to fund R&D and meet capital requirements. It maintains a base shelf prospectus allowing for up to $150 million in securities distribution.
Risk Factors and Contingencies
- Development Risk: REOLYSIN® is still in the research and development stage. There is no assurance that clinical trials will demonstrate safety and efficacy sufficient for regulatory approval.
- Regulatory Risk: The product is subject to intense regulatory approval processes by the FDA, Health Canada, and other authorities. Delays or denials could severely harm the business.
- Manufacturing Dependence: The company relies on third-party contract manufacturers for clinical grade REOLYSIN®. Disruptions in supply could delay trials.
- PFIC Status: The company believes it qualified as a Passive Foreign Investment Company (PFIC) for 2010, which may have adverse U.S. federal income tax consequences for U.S. shareholders.
- Contingent Obligations: The company has a contingent milestone payment of $1.0 million due to former shareholders upon the first receipt of regulatory marketing approval for REOLYSIN®.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the projected burn rate for the Phase III head and neck trial to assess the need for immediate additional financing.
- Warrant Liability: Review the impact of the U.S. GAAP reclassification of warrants with foreign currency exercise prices on the net loss and equity position.
- Clinical Trial Enrollment: Monitor the enrollment rates and interim data releases for the Phase III REO 018 trial, as this is the primary catalyst for future value.
- BCBC Investment: Track the status of the British Canadian Biosciences Corp. investment, currently held for sale, to determine if it will be divested or written down further.
- PFIC Implications: U.S. investors should consult tax advisors regarding the tax consequences of the company's PFIC status.